PharmAust (ASX:PAA) has completed its third cohort of six participants in the Phase 1/2 clinical trial of its lead drug candidate, monepantel (MPL), in Motor Neurone Disease.
Having announced the completion of recruitment for treatment level 3, PharmAust said it had completed the day 28 dosing of the final patient in the third cohort.
It said Cohorts 1, 2 and 3 participants have elected to continue on MPL treatment.
"All participants have tolerated the MPL tablets well, and the Safety Monitoring Committee will review data from each dosage level for safety and pharmacokinetic effects," said the company.
The Phase 1/2 clinical study is investigating the tolerability, safety, pharmacokinetics and preliminary efficacy of oral MPL in patients living with MND. The trial is open-label and comprises a four-week escalating dose of MPL.